Home > Press > Learn about the Biologic Imaging Reagents: Technologies and Global Markets
Abstract:
Reportlinker.com announces that a new market research report related to the Diagnostic equipment industry is available in its catalogue.
Biologic Imaging Reagents: Technologies and Global Markets
www.reportlinker.com/p099465/Biologic-Imaging-Reagents-Technologies-and-Global-Markets.html
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC's goal for this study is to determine the global market and future demand growth for biologic imaging reagents over a five-year period from 2008 to 2013. Our particular interest is to characterize and quantify the biologic imaging reagents market potential by technology, reagent type and end user market. We also evaluate future growth opportunities in emerging biologic imaging reagents such as quantum dots, nanoparticles, fluorescent proteins and supermolecules.
Imaging reagent types covered include fluorescent probes and dyes; fluorescent proteins; nanoparticles; fullerene and dendrimer supermolecules; magnetic resonance imaging; ultrasound and x-ray contrast reagents; and imaging radiopharmaceuticals.
Our key objective is to present a comprehensive discussion of where the state-of-the-art is in biologic imaging reagents and forecast the future commercial potential for the key market segments. This discussion will provide a basis for companies to make strategic choices about developing new products and markets, or employing biologic imaging reagents. The study will benefit reagent and instrument manufacturers; users of biologic imaging reagents; medical instrument companies; life sciences tools companies; diagnostic and drug manufacturers; biotechnology companies; and developers of nanotechnologies.
REASONS FOR DOING THE STUDY
Biologic imaging reagents play an important role in the medical, pharmaceutical, diagnostic, biotechnology and life sciences tools industries. Imaging and detection technologies are used extensively in medicine, biotechnology and pharmaceutical research. Traditional imaging techniques, such as x-ray, computer tomography (CT), ultrasound (US), magnetic resonance imaging (MRI) and nuclear medicine (NM), mainly analyze anatomy and morphology and cannot detect changes at the molecular level. However, new developments in biotechnology allow us to image at the cellular and molecular level, paving the way for earlier diagnosis and treatment of disease. Biologic imaging reagents play a critical role in this medical revolution.
At the same time, tremendous advances in genomics, proteomics and cellular analysis are assisted by imaging technologies including fluorescent dyes and probes, quantum dot nanoparticles, and fluorescent proteins. Growth in technologies such as biochips, DNA sequencing, and PCR relies on sensitive biologic fluorescent imaging reagents.
Advances in technologies that are used in biologic imaging reagents are also moving forward at a rapid pace. These technologies include nanotechnology, biologic targeting, microfluidics, supramolecular chemistry and protein engineering. Rapid developments across a number of technology fields promise to change the biologic imaging industry by enabling novel imaging reagents and unique market opportunities. This report analyzes these developments and their impact on the future markets for biologic imaging reagents.
Given these market and technology dynamics, it is especially timely to examine the biologic imaging reagents market.
INTENDED AUDIENCE
We have compiled a study of existing and future imaging reagent technologies that will be commercially important in the major end user segments including life science research tools, drug discovery and development, and diagnostics.
We present the various imaging reagent technologies, including fluorescent probes and dyes; nanomaterials; fluorescent proteins; supermolecules; contrast reagents, and imaging radiopharmaceuticals. We also examine the industry growth driving forces; product types; market applications; companies and industry alliances and acquisitions; future market potential and product sales forecasts for the period 2008 through 2013. We project the future use of biologic imaging reagents in the main end user segments and by technology.
This study will be of particular interest to life science research tools suppliers, pharmaceutical manufacturers, diagnostics, biotechnology, genomics, proteomics, nanotechnology and supramolecular companies. It will also be of interest to companies making products for medical imaging, microarrays, lab on a chip, polymerase chain reaction (PCR), molecular diagnostics assays, fluorescence in-situ hybridization (FISH), fluorescence activated cell sorting (FACS) as well as medical researchers and clinicians.
CHAPTER ONE: INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF REPORT
METHODOLOGY
INFORMATION SOURCES
RELATED BCC REPORTS
ANALYST CREDENTIALS
BCC RESEARCH ONLINE SERVICES
DISCLAIMER
CHAPTER TWO: SUMMARY
SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, 2006-2013 ($ MILLIONS)
SUMMARY (CONTINUED)
CHAPTER THREE: OVERVIEW
INTRODUCTION
BIOLOGIC IMAGING TECHNOLOGIES COVERED IN THIS REPORT
TABLE 1 SCOPE OF THIS REPORT
MARKET POTENTIAL OF BIOLOGIC REAGENTS PRODUCTS
TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY, THROUGH 2013 ($ MILLIONS)
TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2013 ($ MILLIONS)
FORCES DRIVING BIOLOGIC IMAGING REAGENTS INDUSTRY GROWTH
TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
FORCES DRIVING BIOLOGIC
(CONTINUED)
LIFE CYCLE STATUS OF BIOLOGIC IMAGING REAGENTS TECHNOLOGIES
TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS
THE BIOLOGIC IMAGING REAGENTS INDUSTRY
TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPETITORS
THE BIOLOGIC IMAGING REAGENTS
(CONTINUED)
CHAPTER FOUR: BIOLOGIC IMAGING TECHNOLOGIES
IMAGING REAGENT TYPES
TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES
IN-VIVO IMAGING MODALITIES
TABLE 8 IN-VIVO IMAGING MODALITIES
TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES
IN-VIVO IMAGING MODALITIES (CONTINUED)
MOLECULAR IMAGING
IN-VITRO IMAGING/DETECTION
TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING
TRENDS IN IN-VIVO IMAGING
TABLE 11 KEY TRENDS FOR IN-VIVO IMAGING
TRENDS IN IN-VIVO IMAGING (CONTINUED)
BIOLOGIC IMAGING REAGENTS TECHNOLOGIES
NANOPARTICLES
TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS
Nanoparticles (Continued)
TABLE 13 COMPARISON OF ANTIBODY CONJUGATE NANOPARTICLES
FLUORESCENT DYES AND PROBES
TABLE 14 FLUORESCENT DYES AND PROBES
Fluorescent Dyes and Probes (Continued)
TABLE 15 ADVANTAGES OF FLUORESCENCE VERSUS TRADITIONAL METHODS
TABLE 16 FLUORESCENT DYE PERFORMANCE CRITERIA
FLUORESCENT PROTEINS
TABLE 17 TYPES OF FLUORESCENT PROTEINS
Fluorescent Proteins (Continued)
Genetically Engineering Fluorescent Proteins
TABLE 18 PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES
Engineered Fluorescent Cell Lines
Emerging Fluorescent Protein Applications
TABLE 19 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS
Comparison of Fluorescent Proteins with Fluorescent
Dyes
TABLE 20 FLUORESCENT PROTEINS VERSUS DYES
Technology Challenges
TABLE 21 TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS
SUPERMOLECULES
TABLE 22 CLASSIFICATION OF IMAGING SUPERMOLECULES
SUPERMOLECULES (Continued)
FIGURE 1 MOLECULAR ENGINEERING OF DENDRIMER IMAGING SUPERMOLECULES
QUANTUM DOTS
TABLE 23 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT PROTEINS
FIGURE 2 QUANTUM DOT SPECTRA
FIGURE 3 FLUORESCENT DYE SPECTRA
Quantum Dots (Continued)
TABLE 24 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS
RADIOPHARMACEUTICALS
CONTRAST REAGENTS
Contrast Reagents (Continued)
Contrast Reagents (Continued)
EMERGING CLASSES OF IMAGING REAGENTS
COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY
FIGURE 4 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY
ADVANCED IMAGING REAGENT FUNCTIONS
TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS
Dual Modality Reagents
Multifunctional Reagents
Multifunctional Reagents (Continued)
Multiplexed Reagents
BIOLOGIC IMAGING REAGENTS MANUFACTURING COSTS
FIGURE 5 MANUFACTURING COSTS OF IMAGING REAGENT CLASSES
BIOLOGIC IMAGING REAGENTS
(CONTINUED)
COMPARISON OF IMAGING REAGENT TECHNOLOGY PLATFORMS
TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES
TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS
TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS
COMPARISON OF IMAGING
(CONTINUED)
CHAPTER 5: BIOLOGIC IMAGING REAGENTS APPLICATIONS
OVERVIEW
TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS
TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND MEDICAL INDUSTRIES
TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT
TABLE 31 (CONTINUED)
TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS
RESEARCH AND DEVELOPMENT
TABLE 33 R&D TOOLS
TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS
DRUG DISCOVERY AND DEVELOPMENT
TABLE 35 DRUG DISCOVERY & DEVELOPMENT
INFLUENCE OF IMAGING TECHNOLOGY ON DRUG DEVELOPMENT
ATTRITION RATE OF LEAD COMPOUNDS
FIGURE 6 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT
FLUORESCENT PROTEIN APPLICATIONS IN DRUG DISCOVERY
IN-VIVO SMALL ANIMAL IMAGING APPLICATIONS
TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES
TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING
MICRODOSING
Biomarkers for Microdosing
TABLE 38 BIOMARKERS FOR MICRODOSING
Regulatory Requirements for Microdosing
Imaging Modalities for Microdosing
TABLE 39 MICRODOSING IMAGING MODALITIES
Status of Microdosing
DIAGNOSTICS
INTRODUCTION
TABLE 40 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS
TABLE 40 (CONTINUED)
DIAGNOSTIC APPLICATIONS OF IMAGING REAGENTS
TABLE 41 DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS
Fluorescent Dyes, Probes and Tags
Nanoparticles
Supermolecules
Imaging Radiopharmaceuticals
Contrast Reagents
MOLECULAR IMAGING
Introduction
TABLE 42 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING
Optical Molecular Imaging Reagents Status
TABLE 43 FLUORESCENCE IMAGING REAGENTS PIPELINE STATUS
PET/SPECT Molecular Imaging Reagents Status
TABLE 44 PET/SPECT IMAGING REAGENTS PIPELINE STATUS
TABLE 44 (CONTINUED)
PET/SPECT
(Continued)
Biological Processes Associated with Molecular PET Imaging Reagents
TABLE 45 PET IMAGING REAGENT APPLICATIONS
Biological Processes
(Continued)
CASE STUDY: ALZHEIMER'S DISEASE IMAGING REAGENT OPPORTUNITIES
FIGURE 7 ALZHEIMER'S DISEASE'S PATHOLOGY PROGRESSION
MR IMAGING REAGENTS
TABLE 46 EXISTING AND EMERGING MRI IMAGING REAGENTS STATUS
TABLE 46 (CONTINUED)
ULTRASOUND IMAGING REAGENTS
NANOPARTICLES IN DIAGNOSTICS
TABLE 47 NANOPARTICLE IN-VIVO DIAGNOSTICS PIPELINE
TABLE 48 NANOSPHERE IN-VITRO DIAGNOSTICS REAGENTS PIPELINE
HYBRID DIAGNOSTIC/THERAPEUTIC APPLICATIONS
TABLE 49 HYBRID IMAGING/THERAPEUTIC APPLICATIONS
Hybrid Diagnostic/
(Continued)
CHAPTER SIX: BIOLOGIC IMAGING REAGENTS INDUSTRY STRUCTURE
MEDICAL IMAGING INSTRUMENT INDUSTRY
TABLE 50 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES
INNOVATION WITHIN THE IMAGING REAGENT INDUSTRY
ROLE OF CORE IMAGING FACILITIES
ROLE OF STRATEGIC ALLIANCES
TABLE 51 RECENT IMAGING REAGENT STRATEGIC ALLIANCES
TABLE 51 (CONTINUED)
TABLE 51 (CONTINUED)
Role of Strategic Alliances (Continued)
TABLE 52 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2005-2008
TABLE 52 (CONTINUED)
TABLE 52 (CONTINUED)
TABLE 52 (CONTINUED)
2005
2006
2006 (Continued)
2007
2008
SPECIALIZED INDUSTRY SECTORS
FLUORESCENT DYES AND PROBES
TABLE 53 FLUORESCENT DYES AND PROBES KEY COMPETITORS
QUANTUM DOTS
TABLE 54 QUANTUM DOTS KEY COMPETITORS
TABLE 54 (CONTINUED)
CONTRAST REAGENTS
TABLE 55 CONTRAST REAGENTS KEY COMPETITORS
RADIOPHARMACEUTICALS
TABLE 56 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES
Radioactive Isotope Supply Industry
SMALL ANIMAL IN-VIVO IMAGING
TABLE 57 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING COMPETITORS
CARDIAC IMAGING
TABLE 58 CARDIAC IMAGING REAGENT COMPETITIVE SPACE
FLUORESCENT PROTEINS
TABLE 59 FLUORESCENT PROTEIN PRODUCERS
ANTIBODY BIOTECHNOLOGY COMPANIES
TABLE 60 ANTIBODY BIOTECHNOLOGY COMPANIES WHO HAVE INTEREST IN IMAGING REAGENTS
CHAPTER SEVEN: BIOLOGIC IMAGING REAGENTS MARKETS
GROWTH DRIVING FORCES
TABLE 61 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
GROWTH DRIVING FORCES (CONTINUED)
RADIOPHARMACEUTICALS
TABLE 77 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2013 ($ MILLIONS)
TABLE 78 GLOBAL VALUE OF ONCOLOGY RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2013 ($ MILLIONS)
TABLE 79 GLOBAL VALUE OF ONCOLOGY RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
TABLE 80 GLOBAL VALUE OF FDG RADIOPHARMACEUTICAL REAGENTS, BY DISEASE CLASS, THROUGH 2013 ($ MILLIONS)
OPTICAL IMAGING REAGENTS
TABLE 81 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY APPLICATION, THROUGH 2013 ($ MILLIONS)
TABLE 82 GLOBAL VALUE OF IN-VITRO RESEARCH AND DRUG DISCOVERY AND DEVELOPMENT OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY, THROUGH 2013 ($ MILLIONS)
TABLE 83 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 84 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 85 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 86 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE, THROUGH 2013 ($ MILLIONS)
OPTICAL IMAGING REAGENTS (Continued)
TABLE 87 GLOBAL VALUE OF IN-VITRO DIAGNOSTIC FLUORESCENT OPTICAL IMAGING REAGENTS, BY MARKET SEGMENT, THROUGH 2013 ($ MILLIONS)
TABLE 88 GLOBAL VALUE OF OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
GEOGRAPHICAL
TABLE 89 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH 2013 ($ MILLIONS)
Geographical (Continued)
CHAPTER EIGHT: PATENT STATUS
IMAGING REAGENTS PATENTS BY SELECTED TECHNOLOGY
TABLE 90 NUMBER OF PATENTS BY TECHNOLOGY
FLUORESCENCE REAGENTS
TABLE 91 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
FLUORESCENT PROTEINS
TABLE 92 FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
DENDRIMERS
TABLE 93 DENDRIMER PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
TABLE 94 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
PATENTS BY COMPANY
FIGURE 8 PATENTS BY COMPANY FOR MARKET SEGMENTS
LITIGATION STATUS
TABLE 95 IP LITIGATION STATUS
CHAPTER NINE: COMPANY PROFILES
ACUSPHERE, INC.
TABLE 96 ACUSPHERE PRODUCT PIPELINE
TABLE 97 ACUSPHERE PATENT ESTATE
TABLE 97 (CONTINUED)
ADVANCED RESEARCH TECHNOLOGIES INC.
AFFIBODY AB
AION DIAGNOSTICS
ALNIS BIOSCIENCES INC.
ALSERES PHARMACEUTICALS INC.
AMAG PHARMACEUTICALS
TABLE 98 AMAG MOLECULAR IMAGING REAGENTS PIPELINE
TABLE 99 AMAG MRI IMAGING REAGENTS MARKETING ALLIANCES
ANTICANCER INC
AVID RADIOPHARMACEUTICALS
TABLE 100 AVID DIAGNOSTIC IMAGING PIPELINE
BAYER SCHERING PHARMA AG
BBI INTERNATIONAL
BD BIOSCIENCES
BECKMAN COULTER, INC.
BIOFORCE NANOSCIENCES HOLDINGS, INC.
BIOMODA INC.
BIOPHAN TECHNOLOGIES, INC
BIOSEARCH TECHNOLOGIES, INC.
BIOSCEPTRE
BIOTAGE AB
BRACCO DIAGNOSTICS INC
CALIPER LIFE SCIENCES, INC.
CAMBRIDGE ISOTOPE LABORATORIES, INC.
CAPSULUTION NANOSCIENCES AG
CARDINAL HEALTH
CARESTREAM HEALTH, INC
CELLCYTE GENETICS
CHEMICELL GMBH
CHINA MEDICAL TECHNOLOGIES, INC.
COVIDIEN
DENDRITECH, INC.
DO-COOP TECHNOLOGIES
EBIOSCIENCE, INC.
EPIX PHARMACEUTICALS
EPIX Pharmaceuticals (Continued)
EVIDENT TECHNOLOGIES
EVROGEN
FERROPHARM GMBH
FLUOROPHARMA
TABLE 101 FLUORPHARMA PET IMAGING REAGENT PIPELINE
FLUOROTECHNICS PTY LTD.
Fluorotechnics Pty Ltd. (Continued)
GE HEALTHCARE
TABLE 102 GE HEALTHCARE IMAGING REAGENTS PIPELINE
GUERBET
IBA MOLECULAR
IMMUNICON
INDEC BIOSYSTEMS
INVITROGEN
Invitrogen (Continued)
JUBILANT ORGANOSYS LTD
TABLE 103 JUBILANT ORGANOSYS MEDICAL IMAGING REAGENT PIPELINE
Jubilant Organosys Ltd. (Continued)
KEREOS, INC.
TABLE 104 KEREOS IMAGING REAGENTS PIPELINE
TABLE 105 KEREOS STRATEGIC ALLIANCES
KPL, INC.
LANTHEUS MEDICAL IMAGING
TABLE 106 LANTHEUS DIAGNOSTIC IMAGING PIPELINE
LUNA NANOWORKS
MARINPHARM GMBH
MBL INTERNATIONAL
MOLECULAR INSIGHT PHARMACEUTICALS
MOLECULAR TARGETING TECHNOLOGIES, INC
TABLE 107 MTTI IMAGING REAGENTS PIPELINE
NANOCO TECHNOLOGIES LTD.
NANOPROBES, INC.
NANOSPECTRA BIOSCIENCES
NANOSPHERE, INC.
TABLE 108 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE
OXONICA INC.
PHILIPS HEALTHCARE
PROMEGA CORPORATION
SELAH TECHNOLOGIES, LLC
SIEMENS AG
Siemens AG (Continued)
SIGNALOMICS GMBH
STARPHARMA HOLDINGS LTD
Starpharma Holdings Ltd. (Continued)
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC
TK SIGNAL
VISEN MEDICAL INC.
WILEX AG
TABLE 109 WILEX PRODUCT PIPELINE
LIST OF TABLES
SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING
REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 1 SCOPE OF THIS REPORT
TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY
TECHNOLOGY, THROUGH 2013 ($ MILLIONS)
TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY
END USER MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS
TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPETITORS
TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES
TABLE 8 IN-VIVO IMAGING MODALITIES
TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES
TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING
TABLE 11 KEY TRENDS FOR IN-VIVO IMAGING
TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS
TABLE 13 COMPARISON OF ANTIBODY CONJUGATE
NANOPARTICLES
TABLE 14 FLUORESCENT DYES AND PROBES
TABLE 15 ADVANTAGES OF FLUORESCENCE VERSUS TRADITIONAL
METHODS
TABLE 16 FLUORESCENT DYE PERFORMANCE CRITERIA
TABLE 17 TYPES OF FLUORESCENT PROTEINS
TABLE 18 PHOTOACTIVABLE AND PHOTOCONVERTIBLE
FLUORESCENT PROTEIN TYPES
TABLE 19 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS
TABLE 20 FLUORESCENT PROTEINS VERSUS DYES
TABLE 21 TECHNOLOGY CHALLENGES FOR FLUORESCENT
PROTEINS
TABLE 22 CLASSIFICATION OF IMAGING SUPERMOLECULES
TABLE 23 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES
AND FLUORESCENT PROTEINS
TABLE 24 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS
TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT
FUNCTIONS
TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT
TECHNOLOGIES
TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT
PLATFORMS
TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING
REAGENTS
TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS
TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE
SCIENCES AND MEDICAL INDUSTRIES
TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET
SEGMENT
TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS
TABLE 33 R&D TOOLS
TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING
REAGENTS IN R&D TOOLS
TABLE 35 DRUG DISCOVERY & DEVELOPMENT
TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES
TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL
IMAGING
TABLE 38 BIOMARKERS FOR MICRODOSING
TABLE 39 MICRODOSING IMAGING MODALITIES
TABLE 40 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS
TABLE 41 DIAGNOSTIC APPLICATIONS OF SELECTED
IMAGING REAGENTS
TABLE 42 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR
IMAGING
TABLE 43 FLUORESCENCE IMAGING REAGENTS PIPELINE STATUS
TABLE 44 PET/SPECT IMAGING REAGENTS PIPELINE STATUS
TABLE 45 PET IMAGING REAGENT APPLICATIONS
TABLE 46 EXISTING AND EMERGING MRI IMAGING REAGENTS
STATUS
TABLE 47 NANOPARTICLE IN-VIVO DIAGNOSTICS PIPELINE
TABLE 48 NANOSPHERE IN-VITRO DIAGNOSTICS REAGENTS
PIPELINE
TABLE 49 HYBRID IMAGING/THERAPEUTIC APPLICATIONS
TABLE 50 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING
COMPANIES
TABLE 51 RECENT IMAGING REAGENT STRATEGIC ALLIANCES
TABLE 52 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS,
2005-2008
TABLE 53 FLUORESCENT DYES AND PROBES KEY COMPETITORS
TABLE 54 QUANTUM DOTS KEY COMPETITORS
TABLE 55 CONTRAST REAGENTS KEY COMPETITORS
TABLE 56 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES.... 113
TABLE 57 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING
COMPETITORS
TABLE 58 CARDIAC IMAGING REAGENT COMPETITIVE SPACE
TABLE 59 FLUORESCENT PROTEIN PRODUCERS
TABLE 60 ANTIBODY BIOTECHNOLOGY COMPANIES WHO HAVE
INTEREST IN IMAGING REAGENTS
TABLE 61 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING
FORCES
TABLE 62 GLOBAL VALUE OF INSTRUMENTS AND ASSAYS
UTILIZING BIOLOGIC IMAGING REAGENTS, THROUGH 2013
($ MILLIONS)
TABLE 63 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY
TECHNOLOGY, THROUGH 2013 ($ MILLIONS)
TABLE 64 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS
MARKET, BY END USE, THROUGH 2013 ($ MILLIONS)
TABLE 65 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY
FUNCTION, THROUGH 2013 ($ MILLIONS)
TABLE 66 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY
END USER MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 67 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY
MODALITY, THROUGH 2013 ($ MILLIONS)
TABLE 68 GLOBAL VALUE OF FLUORESCENT PROTEIN REAGENTS,
BY TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 69 GLOBAL VALUE OF IMAGING NANOPARTICLES BY
TECHNOLOGY THROUGH 2013 ($ MILLIONS)
TABLE 70 GLOBAL VALUE OF CONTRAST AGENTS MARKET, BY
MODALITY, THROUGH 2013 ($ MILLIONS)
TABLE 71 GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE,
THROUGH 2013 ($ MILLIONS)
TABLE 72 GLOBAL VALUE OF MRI GD CHELATE REAGENTS, BY
PRODUCT, THROUGH 2013 ($ MILLIONS)
TABLE 73 GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, BY
PRODUCT, THROUGH 2013 ($ MILLIONS)
TABLE 74 GLOBAL SALES OF MRI CONTRAST REAGENTS, BY
PROCEDURE, THROUGH 2013 ($ MILLIONS)
TABLE 75 GLOBAL VALUE OF ULTRASOUND REAGENTS MARKET, BY
TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 76 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY
TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 77 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING
REAGENTS MARKET, BY INDICATION, THROUGH 2013
($ MILLIONS)
TABLE 78 GLOBAL VALUE OF ONCOLOGY
RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
INDICATION, THROUGH 2013 ($ MILLIONS)
TABLE 79 GLOBAL VALUE OF ONCOLOGY
RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
PRODUCT, THROUGH 2013 ($ MILLIONS)
TABLE 80 GLOBAL VALUE OF FDG RADIOPHARMACEUTICAL
REAGENTS, BY DISEASE CLASS, THROUGH 2013 ($ MILLIONS)
TABLE 81 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING
REAGENTS MARKET, BY APPLICATION, THROUGH 2013
($ MILLIONS)
TABLE 82 GLOBAL VALUE OF IN-VITRO RESEARCH AND DRUG
DISCOVERY AND DEVELOPMENT OPTICAL FLUORESCENT
IMAGING REAGENTS MARKET, BY ASSAY, THROUGH 2013
($ MILLIONS)
TABLE 83 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL
FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE,
THROUGH 2013 ($ MILLIONS)
TABLE 84 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL
FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE,
THROUGH 2013 ($ MILLIONS)
TABLE 85 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO
OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY
ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 86 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING
REAGENTS, BY END USE, THROUGH 2013 ($ MILLIONS)
TABLE 87 GLOBAL VALUE OF IN-VITRO DIAGNOSTIC FLUORESCENT
OPTICAL IMAGING REAGENTS, BY MARKET SEGMENT, THROUGH
2013 ($ MILLIONS)
TABLE 88 GLOBAL VALUE OF OPTICAL IMAGING REAGENTS, BY
TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 89 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY
GEOGRAPHY, THROUGH 2013 ($ MILLIONS)
TABLE 90 NUMBER OF PATENTS BY TECHNOLOGY
TABLE 91 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY
COMPANY (NUMBER OF PATENTS)
TABLE 92 FLUORESCENT PROTEIN PATENT ASSIGNEES BY
COMPANY (NUMBER OF PATENTS)
TABLE 93 DENDRIMER PATENT ASSIGNEES BY COMPANY (NUMBER
OF PATENTS)
TABLE 94 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY
(NUMBER OF PATENTS)
TABLE 95 IP LITIGATION STATUS
TABLE 96 ACUSPHERE PRODUCT PIPELINE
TABLE 97 ACUSPHERE PATENT ESTATE
TABLE 98 AMAG MOLECULAR IMAGING REAGENTS PIPELINE
TABLE 99 AMAG MRI IMAGING REAGENTS MARKETING ALLIANCES
TABLE 100 AVID DIAGNOSTIC IMAGING PIPELINE
TABLE 101 FLUORPHARMA PET IMAGING REAGENT PIPELINE
TABLE 102 GE HEALTHCARE IMAGING REAGENTS PIPELINE
TABLE 103 JUBILANT ORGANOSYS MEDICAL IMAGING REAGENT
PIPELINE
TABLE 104 KEREOS IMAGING REAGENTS PIPELINE
TABLE 105 KEREOS STRATEGIC ALLIANCES
TABLE 106 LANTHEUS DIAGNOSTIC IMAGING PIPELINE
TABLE 107 MTTI IMAGING REAGENTS PIPELINE
TABLE 108 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE
TABLE 109 WILEX PRODUCT PIPELINE
LIST OF FIGURES
SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING
REAGENTS, BY TYPE, 2006-2013 ($ MILLIONS)
FIGURE 1 MOLECULAR ENGINEERING OF DENDRIMER IMAGING
SUPERMOLECULES
FIGURE 2 QUANTUM DOT SPECTRA
FIGURE 3 FLUORESCENT DYE SPECTRA
FIGURE 4 THREE COMPONENTS OF ADVANCED IMAGING REAGENT
TECHNOLOGY
FIGURE 5 MANUFACTURING COSTS OF IMAGING REAGENT
CLASSES
FIGURE 6 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG
DEVELOPMENT
FIGURE 7 ALZHEIMER'S DISEASE'S PATHOLOGY PROGRESSION
FIGURE 8 PATENTS BY COMPANY FOR MARKET SEGMENTS
To order this report:
Biologic Imaging Reagents: Technologies and Global Markets
####
For more information, please click here
Contacts:
Reportlinker
Nicolas:
US: (805)-652-2626
Intl: +1 805-652-2626
Copyright © Business Wire 2009
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Imaging
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||